402 chapter 7 Table 5. Univariate between-group differences in ThyPRO scale scores Patient score, between-group difference Baseline 3 months 6 months 12 months ThyPRO mean SD p* mean SD p* mean SD p* mean SD p* Goitre Symptoms Malignant 21.4 18.5 0.93 25.5 21.5 0.71 21.5 21.5 0.80 15.7 17.7 0.84 Benign 21.7 16.2 ref. 27.3 21.2 ref. 20.3 20 ref. 14.9 17.4 ref. Active surveillance 20.2 14.1 0.67 17.5 14.9 0.01§ 17.0 12.0 0.34 19.2 14.9 0.25 Hyperthyroid Symptoms Malignant 13.3 16.3 0.33 16.1 19.0 0.67 17.5 19.8 0.61 16.4 16.9 0.21 Benign 16.8 18.0 ref. 17.8 18.0 ref. 19.8 21.2 ref. 21.4 21.1 ref. Active surveillance 15.6 14.8 0.75 16.9 15.4 0.81 14.9 15.2 0.22 15.1 13.9 0.10 Hypothyroid Symptoms Malignant 20.6 23.4 0.72 21.7 25.6 0.74 24.1 25.4 0.96 22.2 23 0.75 Benign 22.5 25.0 ref. 19.9 23.3 ref. 24.4 26.2 ref. 23.9 26.1 ref. Active surveillance 21.0 27.2 0.82 22.2 24.0 0.69 23.9 22.3 0.92 19.5 22.5 0.43 Eye Symptoms Malignant 10.8 18.5 0.84 16.3 21.3 0.62 15.5 19.7 0.75 11.5 14.8 0.34 Benign 11.5 17.4 ref. 14.0 18.9 ref. 14.1 16.5 ref. 14.8 17.3 ref. Active surveillance 13.2 17.6 0.69 12.4 18.3 0.71 12.7 15.6 0.69 12.2 17.8 0.54 Tiredness Malignant 29.6 24.1 0.35 32.9 23.9 0.12 33.7 23.6 0.59 32.4 23.4 0.47 Benign 34.5 23.1 ref. 41.2 25.0 ref. 36.5 25.5 ref. 36.1 23.3 ref. Active surveillance 31.3 20.4 0.52 30.1 19.1 0.02 31.3 20.2 0.31 29.4 17.5 0.14 Cognitive Impairment Malignant 15.3 20.8 0.34 22.6 23.8 0.72 22.8 22.9 0.62 19.2 18.7 0.10 Benign 19.7 20.9 ref. 24.5 21.8 ref. 25.3 21.8 ref. 26.3 23.1 ref. Active surveillance 16.6 20.0 0.52 16.4 20.0 0.09§ 15.7 21.5 0.06§ 16.8 20.0 0.05§ Anxiety Malignant 23.2 21.1 0.15 25.3 23.8 0.36 22.1 22.7 0.31 16.0 18.5 0.05 Benign 29.8 20.1 ref. 30.1 24.3 ref. 27.2 25.1 ref. 24.7 23.4 ref. Active surveillance 21.0 19.8 0.06 18.2 21.1 0.02§ 18.8 18.3 0.08 19.5 22.4 0.33 Depressivity Malignant 23.5 24.0 0.44 26.7 24.5 0.78 26.4 24.9 0.44 21.7 19.0 0.17 Benign 27.5 22.8 ref. 28.2 23.1 ref. 30.6 26.2 ref. 27.8 23.1 ref. Active surveillance 21.9 19.7 0.25 16.3 15.8 0.005§ 20.2 17.6 0.03§ 20.1 17.8 0.09§ Emotional Susceptibility Malignant 23.8 23.2 0.25 28.1 22.7 0.42 26.6 23.5 0.27 23.0 20.5 0.08 Benign 29.5 19.5 ref. 32.2 22.7 ref. 32.3 24.4 ref. 31.3 23.3 ref. Active surveillance 21.4 18.9 0.08 19.7 18.1 0.007§ 20.7 14.9 0.005§ 24.0 18.4 0.12 Social Impairment Malignant 9.8 16.5 0.99 14.6 19.7 0.68 16.1 24.1 0.55 10.6 18.9 0.65 Benign 9.8 16.8 ref. 12.8 18.7 ref. 19.3 26.2 ref. 12.5 22.8 ref. Active surveillance 11.2 14.8 0.70 6.9 15.2 0.12 8.8 17.5 0.03§ 7.3 13.0 0.16 Impaired Daily Life Malignant 13.0 21.4 0.54 22.9 28.2 0.93 19.7 22.8 1 15.7 23.8 0.77 Benign 10.3 15.9 ref. 22.4 26.2 ref. 19.7 26.2 ref. 14.3 21.6 red Active surveillance 9.1 16.6 0.76 7.0 12.6 <0.001§ 8.1 15.2 0.007§ 4.9 11.2 0.006§ Impaired Sex Life Malignant 17.6 28.4 0.67 22.0 31.4 0.40 22 33.1 0.81 19.4 32.6 0.53 Benign 20.3 29.9 ref. 27.8 31.7 ref. 23.8 31.9 ref. 23.8 31.7 ref. Active surveillance 23.8 34.1 0.66 17 28.7 0.12 19.2 29.8 0.53 16.7 31.6 0.35 Cosmetic Complaints Malignant 8.5 15.5 0.30 16.7 21.9 0.89 13.4 22.7 0.15 11.5 20.4 0.20 Benign 12.3 18.5 ref. 17.3 20.3 ref. 20.7 24.5 ref. 17.4 22.8 ref. Active surveillance 13.7 15.7 0.73 7.7 11.6 0.004§ 12.7 18.9 0.10 10.5 13.8 0.08 Negative Influence on QoL Malignant 23.5 33.7 0.78 31.5 35.3 0.82 24.5 29.0 0.68 17.9 30.7 0.96 Benign 25.5 32.7 ref. 29.7 40.7 ref. 21.9 29.1 ref. 18.3 30.8 ref. Active surveillance 20.5 28.2 0.49 14.1 27.6 0.03§ 14.2 22.9 0.20 10.7 18.3 0.15 ThyPRO Composite QoL Malignant 21.5 19.7 0.33 26.7 20.9 0.48 25.5 19.7 0.40 21.1 17.1 0.17 Benign 25.5 15.7 ref. 29.9 19.4 ref. 29.2 20.5 ref. 26.4 18.8 ref. Active surveillance 20.4 16.0 0.19 18.0 15.6 0.002§ 18.7 13.7 0.005§ 19.1 14.2 0.05
RkJQdWJsaXNoZXIy MTk4NDMw